Castles J J, Moore T L, Vaughan J H, Bolzan J A, Lee M, Lidsky M D, Caldwell J R, Ehrlich G E, Sharp J T, Kaye R
Arch Intern Med. 1978 Mar;138(3):362-6.
In a double-blind, crossover study, naproxen, 250 mg twice a day, naproxen, 500 mg taken at bedtime, and indomethacin, 25 mg four times a day, were compared in 132 patients with rheumatoid arthritis; six centers participated in the study. Objective indices of arthritis activity, such as number of clinically active joints, walking time, and duration of morning stiffness, were nearly identical for the three treatment regimens. Of particular interest was the observation that efficacy of a single daily dose of naproxen was comparable to that of the twice-daily dosage. Naproxen was better tolerated than indomethacin, as shown by a statistically significant difference in the incidence of CNS complaints.
在一项双盲交叉研究中，对132例类风湿性关节炎患者比较了每日两次服用250毫克萘普生、睡前服用500毫克萘普生和每日四次服用25毫克吲哚美辛的疗效；六个中心参与了该研究。三种治疗方案的关节炎活动客观指标，如临床活动关节数、步行时间和晨僵持续时间，几乎相同。特别值得关注的是观察到每日单次剂量萘普生的疗效与每日两次剂量相当。如中枢神经系统不良反应发生率的统计学显著差异所示，萘普生的耐受性优于吲哚美辛。
